AT
Allyx Therapeutics, Inc.
SEC filingBiotechnology · New Haven, CT
Amount raised$26.4Msold at filing
Total offering$30M$3.6M still open
Investors in the raise32count reported to the SEC
FiledMay 11, 2026first sale May 4, 2026
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Stephen BlochExecutive Officer, Director
Stephen StrittmatterDirector
Robert A BettigoleDirector
Paul FonteyneDirector
Gregory P HoDirector
Timothy A SiegertExecutive Officer
Kevin L. RakinDirector
Executive officers, directors and promoters as listed on the Form D.